Basecamp Research Raises $140M for AI Drug Discovery

London-based Basecamp Research has successfully closed a substantial $140 million Series C funding round, signaling strong investor confidence in its AI-driven approach to therapeutic development. The significant capital infusion was bolstered by strategic investments from artificial intelligence leaders Nvidia and Anthropic, alongside a host of other prominent venture capital firms and institutional backers.

The funding round was spearheaded by S32, the venture capital firm established by Alphabet's former GV founder Bill Maris. Joining S32 in backing Basecamp's ambitious mission were Nvidia's venture arm, NVentures, and Anthropic's Anthology Fund, a collaboration with US VC Menlo Ventures. This marks a significant endorsement from key players at the forefront of AI innovation, underscoring the potential of Basecamp's proprietary technology.

Further strengthening the investor syndicate are new participants including Catalio, the NATO Innovation Fund, Rockefeller, European Tech Collective, and the UK government's Sovereign AI Fund. A cohort of returning investors, including Firebrand, River Capital King Philanthropies, and Redalpine, also reaffirmed their commitment to Basecamp's vision. This diverse group of investors highlights a broad belief in the company's ability to revolutionize drug discovery.

Basecamp Research, founded in 2019, is dedicated to accelerating the design of next-generation treatments for complex diseases such as cancer and autoimmune disorders. The company leverages its proprietary "Eden" biological foundation models, trained on what it claims is the world's most extensive proprietary genomic dataset, gathered through global partnerships. The newly acquired capital will be instrumental in training advanced AI models and advancing its pipeline of AI-designed therapeutics, particularly focusing on in vivo cell therapy.

The company's innovative approach aims to overcome the limitations of current cell therapies, which are often constrained by complexity and prohibitively high manufacturing costs. By integrating AI's capacity to design intricate DNA sequences with specialized delivery enzymes, Basecamp seeks to create more sophisticated, customizable, and accessible cell therapies. This strategy is supported by promising preclinical results across various disease areas, paving the way for clinical development.

The strategic involvement of Nvidia and Anthropic is particularly noteworthy. Nvidia's expertise in high-performance computing and AI infrastructure is crucial for training the complex models Basecamp employs. Anthropic, a leading AI safety and research company, brings cutting-edge advancements in large language models and AI reasoning, which can be adapted for biological applications. This collaboration suggests a synergistic push towards more powerful and reliable AI in life sciences.

This Series C round brings Basecamp Research's total funding to over $225 million. The company's origins trace back to the founders' academic research in synthetic biology and bioengineering, including pioneering off-grid DNA sequencing expeditions. This blend of deep scientific expertise and entrepreneurial drive positions Basecamp to make significant strides in the rapidly evolving field of AI-driven biotechnology, a sector experiencing intense investment activity as the demand for novel therapeutic solutions grows.